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Abstract
Background: Several acute illness severity scores have been proposed for evaluating patients on
admission to intensive care units but these have not been compared for patients with nosocomial
bloodstream infection (nBSI). We compared three severity of illness scoring systems for predicting
mortality in patients with nBSI due to Pseudomonas aeruginosa.
Methods: We performed a historical cohort study on 63 adults in intensive care units with P.
aeruginosa monomicrobial nBSI.
Results: The Acute Physiology, Age, Chronic Health Evaluation II (APACHE II), Sequential Organ
Failure Assessment (SOFA), and Simplified Acute Physiologic Score (SAPS II), were calculated daily
from 2 days prior through 2 days after the first positive blood culture. Calculation of the area under
the receiver operating characteristic (ROC) curve confirmed that APACHE II and SAPS II at day -
1 and SOFA at day +1 were better predictors of outcome than days -2, 0 and day 2 of BSI. By
stepwise logistic regression analysis of these three scoring systems, SAPS II (OR: 13.03, CI95%
2.51–70.49) and APACHE II (OR: 12.51, CI95% 3.12–50.09) on day -1 were the best predictors for
mortality.
Conclusion: SAPS II and APACHE II are more accurate than the SOFA score for predicting
mortality in this group of patients at day -1 of BSI.
Background
Pseudomonas aeruginosa has the highest crude mortality
(39%) among bacteria causing nosocomial BSI [1]. Some
small studies have evaluated the effect of hospital patho-
gens in relation to clinical outcome [2,3]. However, there
is no consensus regarding the best scoring system for eval-
uating prognosis in BSI.
Since the development of the APACHE (Acute Physiolog-
ical and Chronic Health Evaluation) II score [4], many
studies of infectious diseases have used this scoring sys-
tem to characterize the patient's severity of illness [2,3,5].
Several acute illness severity scores have been proposed
for evaluating patients on admission to intensive care
units, but these have not been compared for patients with
nosocomial bloodstream infection (nBSI).
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sion to the intensive care unit has been demonstrated.
However, it has been shown that progression to organ
dysfunction in patients with P. aeruginosa infection is an
ominous sign [5]. The Simplified Acute Physiology Score
(SAPS II) was also developed to be used on admission to
the intensive care unit [6]. Another scoring system, the
Sequential Organ Failure Assessment (SOFA) score,
assesses the incidence and severity of organ dysfunction in
critically ill patients [7]. Most studies of serious infectious
diseases use one of these scoring systems to assess illness
severity [8,9]. However, studies evaluating the outcome of
patients with P. aeruginosa BSI have relied on a single anal-
ysis of APACHE II to calculate mortality risk [10,11].
The purpose of our study was to compare three severity of
illness scoring systems for predicting mortality in ICU
patients with nBSI due to Pseudomonas aeruginosa.
Methods
Setting
The Virginia Commonwealth University Medical Center
(VCUMC) is an 820-bed tertiary care facility in Richmond,
Virginia. The hospital houses 9 intensive care units
(ICUs), including pediatric ICUs and a burn unit. Approx-
imately 30,000 patients are admitted annually.
Study design
Using the Surveillance and Control of Pathogens of Epide-
miological Importance (SCOPE) database of bloodstream
infections occurring at 49 U.S. hospitals [12], we identi-
fied all patients with a nosocomial BSI due to P. aeruginosa
at VCUMC from 1 January 1996 through 31 December
2003. Patients were considered to have had BSI due to P.
aeruginosa if ≥ 1 blood culture was positive for this organ-
ism. Only monomicrobial BSI in ICU patients were
included. Second episodes were excluded. Clinical data
were concurrently collected by infection control practi-
tioners using a standardized case report form. The data
that were collected routinely included age, gender, dura-
tion of hospitalization in the ICU prior to onset of BSI,
predisposing clinical conditions, and bloodstream patho-
gen. Sources of secondary BSI were identified by cultures
obtained from distant sites that yielded the same patho-
gen. Underlying disease was measured by the Charlson
weighted comorbidity index, dichotomized into scores of
<3 and ≥3 points. Adequate empiric antimicrobial treat-
ment was defined as therapy administered within 24
hours after blood culture samples were obtained that
included the administration of any antimicrobial agent to
which the P. aeruginosa was susceptible [13]. The single
exception to the definition was when a susceptible
aminoglycoside was used either alone or in conjunction
with another antimicrobial to which the organism was
resistant. The APACHE II, SOFA and SAPS II scores (Table
1) were calculated retrospectively from 2 days prior
through 2 days after the first positive blood culture. The
most abnormal value for each parameter in each 24-hour
period was recorded. For a single missing value (which
occurred sometimes for bilirubin concentrations), a
replacement was calculated using the mean value of the
result preceding, and the result after, the missing one.
When more than one consecutive result was missing, it
was considered a missing value in the analysis.
Microbiological methods
Blood cultures were processed at the VCUMC clinical lab-
oratory. Blood cultures (each consisting of aerobic and
anaerobic bottles) were processed using the BACTEC®
9240 blood culture system (Becton Dickinson, Sparks
MD). Identification of P. aeruginosa and antibiotic suscep-
tibility testing were performed by the Vitek method
(bioMérieux).
Table 1: Comparison of variables collected in APACHE II, SAPS 
II and SOFA scores.
Variables APACHE II SAPS II SOFA
Physiological values
Age, years X x
Temperature X x
Mean arterial pressure X
Systolic BP x
Vasopressor x
Heart rate X x
Respiratory rate X
Glasgow Coma Score (GCS) X x x
Urinary output (L/day) x x**
Laboratory parameters
Oxygenation A-aDO2 or PaO2 X
PaO2 x* x
Arterial pH X
Serum sodium X x
Serum potassium X x
Serum creatinine X x**
Serum urea level x
Hematocrit X
White blood count X x
Serum HCO3- (venous) only if no ABGs x
Bilirubin level x x
Platelets x
Chronic diseases/
comorbidities
Chronic diseases x
Chronic health points 
(APACHE II)/type of 
admission(SAPS II)
X x
APACHE II score ranges 0–71; SAPS II score ranges 0–146; SOFA 
score ranges 0–24.
x* If ventilated or continuous pulmonary arterial pressure.
x** Creatinine or urine output.
ABG – Arterial Blood GasPage 2 of 6
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For continuous variables, mean values were compared
using two sample t-tests for independent samples. Differ-
ences in proportions were compared using a chi-square
test (χ2) or Fisher's Exact Test when appropriate. Mean val-
ues are reported ± 1 SD. A computation of the area under
a receiver operating characteristic (ROC) curve for
APACHE II, SAPS II and SOFA was performed at days -2, -
1, 0, 1 and 2 of BSI. The sensitivity, specificity, overall cor-
rectness of prediction, and positive and negative predic-
tive values for APACHE II, SAPS II and SOFA scores were
determined. The cut-off points for predicting in-hospital
mortality were identified as the score giving the best
Youden index (sensitivity + specificity - 1) for each scoring
system on the day with the best discriminating power. The
Youden index evaluates the diagnostic efficacy of a test. If
the index is equal to or less than 0, the diagnostic efficacy
of the test is poor. On the other hand, the closer it is to 1,
the higher is its diagnostic value. Odds ratios were calcu-
lated for variables associated with crude mortality. Ninety
five percent confidence intervals were calculated for all
odd ratios. Alpha was set at 0.05. To identify which of the
3 scales best predicted BSI outcome, three different multi-
variable logistic regression models were built. All statisti-
cal analyses were done using the Statistical Package for the
Social Sciences software (SPSS, Chicago, IL, USA).
Results
Study population and patient characteristics
During the study period, a total of 160 nosocomial P. aer-
uginosa BSIs were identified. Of these, 19 cases (11.9%)
were identified in pediatric patients (<18 years of age), 49
were polymicrobial BSI, and 15 cases were monomicro-
bial BSIs with incomplete medical records. Fourteen
patients had infections that were acquired outside the
intensive care unit (ICU) setting. The remaining 63 mon-
omicrobial episodes of BSI caused by P. aeruginosa in ICU
patients were included in the analysis.
Patients included in this study had a mean age of 56 ±
16.4 years (range 19 – 89 years). Sixty percent of patients
were male. The most frequent diagnoses responsible for
hospitalization were trauma (including burn) (27.0%),
gastrointestinal (23.8%), and solid and hematologic
malignancies (19.1%). Among the potential factors pre-
disposing to BSI, central intravascular devices were the
most frequent (88.9%). In 46 patients (73.0%) ventila-
tory support was needed prior to the onset of BSI, as was
hemodialysis in 12 (19.0%). The most frequent sources of
BSI were respiratory (31.7%) and central venous catheter
(20.6%). More than one-half of BSIs (55.6%) occurred
after 21 days of hospitalization. The mean day of BSI was
38 ± 47.9 (range 3 – 323 days). Appropriate empiric anti-
microbial therapy were begun within 24 hours in 52.4%.
Eighteen patients (28.6%) had a Charlson index ≥ 3. The
crude (overall, in hospital) mortality was 47.6%.
Microbiological features
Of the 63 P. aeruginosa isolates included in this study,
73.0% of BSI were caused by imipenem-susceptible P. aer-
uginosa and 27.0% by imipenem-resistant P. aeruginosa.
Mortality and severity of illness scoring systems
Median APACHE II, SAPS II and SOFA scores on the day
of BSI were 23, 46 and 7, respectively. Computation of the
area under the ROC curve (table 2) for APACHE II, SAPS
II and SOFA was performed at days -2, -1, 0, 1 and 2 of
BSI. The values for area under the ROC curve showed that
the three scores had good discriminative power in the pre-
diction of poor outcome. To evaluate the extent to which
the applied scoring systems were valid for predicting mor-
tality in patients with P. aeruginosa nBSI, the sensitivity,
specificity, overall correctness of prediction and positive
and negative predictive values were determined on the
day of greatest area under the curve (day -1 of BSI for
APACHE II and SAPS II, and at day +1 for SOFA). Table 3
shows the utility parameters calculated at the cut-off point
Table 2: Comparison between receiver operating characteristic 
(ROC) curves for APACHE II, SAPS II and SOFA scores at days -
2, -1, 0, 1 and 2 of P. aeruginosa BSI.
Area under the ROC curve
DAYS of BSI -2 -1 0 1 2
APACHE II 0.741 0.821 0.793 0.804 0.787
SAPS II 0.777 0.809 0.793 0.785 0.783
SOFA 0.718 0.762 0.743 0.806 0.783
Table 3: Prediction of subsequent hospital mortality determined on day with the best discriminating power for P. aeruginosa BSI.
Scoring 
system
Day with best 
discriminating 
power
Cut-off 
point*
Youden 
Index
Sensitivity (%) Specificity (%) Overall 
correctness
PPV (%) NPV (%)
APACHE II -1 22 0.579 70.0 87.9 26.0 84.0 76.3
SAPS II -1 33 0.509 93.3 57.6 34.0 66.7 90.5
SOFA +1 5 0.391 81.5 57.6 46.3 61.1 79.2
PPV = positive predictive value, NPV = negative predictive value, * = value giving the best Youden index.Page 3 of 6
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and the highest positive predictive value were found for
the APACHE II score. SAPS II score had the best sensitivity
93.3%; however the best specificity value was found for
APACHE II score (87.9%). The best negative predictive
value (90.5%) was seen with the SAPS II score. As seen in
table 4, the multivariate analysis controlling for other
potential predictors of outcome was done for all the scor-
ing systems on the best discriminating day to identify the
best predictor for mortality. The SAPS II threshold score
was most predictive (OR: 13.03, CI95% 2.51–70.49), fol-
lowed by APACHE II (OR: 12.51, CI95% 3.12–50.09),
and SOFA (OR: 5.49, CI95% 1.56–19.30).
Discussion
Pseudomonas aeruginosa remains an important cause of BSI
and one of the principal pathogens responsible for severe
organ dysfunction. The present study compares the three
most useful severity of illness scoring systems applied in
studies of bloodstream infection. We decided to compare
APACHE II, SAPS II and SOFA on the day of bacteremia
and two days prior to positive blood culture through two
days afterwards in order to determine which scoring sys-
tem was most predictive for mortality.
The ability to assess a complex clinical condition such as
bloodstream infection, using relatively simple scores may
facilitate communication with regards to the severity of
the physiologic process. Our intention is to improve the
assessment of P. aeruginosa BSI so as to identify different
patterns of organ dysfunction, and thereby enhance our
understanding of the infectious process, as well as gaining
knowledge of a patient's prognosis. BSIs should not be
seen as static phenomena, but rather as a continuum of
alterations with changes in the patients' condition seen
daily. Many intrinsic variables are involved (e.g., underly-
ing diseases, age, and gender), but interventional variables
such as adequate initial antibiotic treatment [13], rapid
removal of catheters responsible for perpetuating the
infection [14], and optimization of hemodynamic status
with fluid resuscitation or vasopressors [15,16] may deter-
mine the evolution of this process. If we had calculated
the prognostic scores on our patients at the time of hospi-
tal admission, given that one half of the patients acquired
BSI after 21 days of hospitalization, the prediction of mor-
tality would likely be totally different and would not take
into account the impact of the nosocomial bloodstream
infection.
Many intensive care units receive trauma and surgical
patients and they are able to stratify acutely ill patients
prognostically with success by using APACHE II [4], SAPS
II [6] or SOFA scores [7]. However the proportion of
infected patients in these studies of scoring systems was
less than 30%. To our knowledge, until this point there
has been no study that compares the severity of illness
scoring systems for patients with nosocomial blood-
stream infection. In patients with P. aeruginosa BSI, calcu-
lation of the area under the ROC curve in our study
confirmed that assessing scores at day -1 was best for SAPS
II and APACHE II, while SOFA was best assessed on day
+1 of BSI. Multivariate analysis was performed to control
Table 4: Stepwise logistic regression analysis for each scoring systems with crude mortality at day with the best discriminating power 
for P. aeruginosa BSI.
Died (n = 30) Recovered (n = 33) Univariate analysis Multivariate analysis
VARIABLES AT DAY -1 N % N % OR CI 95% OR CI 95%
APACHE II >22 at day -1 21 84.0 4 16.0 16.92 4.59–62.37 12.51 3.12–50.09
Inadequate antibiotic therapy 16 53.3 14 46.7 1.26 0.75–2.11
Imipenem resistant P. aeruginosa 10 58.8 7 41.2 1.86 0.60–5.74
Charlson score ≥ 3 14 77.8 4 22.2 6.34 1.78–22.54 2.28 0.49–10.63
SAPS II >33 at day -1 28 66.7 14 33.3 19.00 3.87–93.36 13.03 2.51–70.49
Inadequate antibiotic therapy 16 53.3 14 46.7 1.26 0.75–2.11
Imipenem resistant P. aeruginosa 10 58.8 7 41.2 1.86 0.60–5.74
Charlson score ≥ 3 14 77.8 4 22.2 6.34 1.78–22.54 2.50 0.63–9.90
Died (n = 27) Recovered (n = 33) Univariate analysis Multivariate analysis
VARIABLES AT DAY +1 N % N % OR CI 95% OR CI 95%
SOFA > 5 at day + 1 22 61.1 14 38.9 5.97 1.81–19.66 5.49 1.56–19.30
Inadequate antibiotic therapy 14 50.0 14 50.0 0.68 0.25–1.90
Imipenem resistant P. aeruginosa 9 56.3 7 43.8 1.86 0.58–5.90
Charlson score ≥ 3 12 75.0 4 25.0 5.80 1.59–21.11 5.23 1.31–20.90Page 4 of 6
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comorbidity index. This confirmed that SAPS II and
APACHE II on day -1 were the best predictors for mortality
(Table 4).
In the APACHE II and SAPS II studies, calculations were
done only on the day of admission [4,6]. A previous
report showed that the APACHE II score at admission was
not useful as a prognostic factor, whereas the progression
of organ dysfunction after the onset of pneumonia due to
P. aeruginosa in intubated patients was predictive [5].
However, other studies showed increased APACHE II
scores as a risk factor for mortality [3,10]. On the other
hand, in the SOFA study the scores were calculated every
day [7]. Other studies comparing scoring systems in cir-
rhotic patients with renal failure found that the discrimi-
natory power of SOFA for predicting mortality was
superior to the other scoring systems [17].
The limitations of our study should be acknowledged.
First, we performed a retrospective study. Second, we
applied the APACHE II and SAPS II scores daily although
these scores were originally intended to be calculated after
the first 24 hours of ICU care. And lastly, it is a single
center study which limits its generalizability.
Conclusion
In conclusion, the crude mortality rate is high for P. aeru-
ginosa BSI. The data in this study demonstrate that SAPS II
and APACHE II are more accurate than SOFA scores for
predicting mortality in this group of patients. Retrospec-
tively calculating the APACHE II or SAPS II score on the
day preceding the first blood culture yielding P. aerugi-
nosa, could be helpful to clinicians in discussing prognosis
with patients' families. Furthermore, these data can guide
future studies that further delineate the epidemiology of
nosocomial BSI, including efforts to determine which var-
iables may be associated with improved outcome among
patients with nosocomial BSI.
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